Arecor Therapeutics (LON:AREC) Stock Price Down 3.2% – What’s Next?

Arecor Therapeutics plc (LON:AREC) shares fell 3.2% on Thursday . The company traded as low as GBX 75 ($1.01) and last traded at GBX 75 ($1.01). 1 shares changed hands during trading, a decline of 100% from the average session volume of 36,351 shares. The stock had previously closed at GBX 77.50 ($1.04).

Arecor Therapeutics Stock Performance

The stock’s fifty day moving average is GBX 72.20 and its two-hundred day moving average is GBX 53.69. The firm has a market capitalization of £28.32 million, a price-to-earnings ratio of -326.09 and a beta of -0.18. The company has a debt-to-equity ratio of 5.51, a quick ratio of 6.24 and a current ratio of 1.37.

Arecor Therapeutics (LON:AREC) last released its quarterly earnings results on Thursday, September 25th. The company reported GBX (7) earnings per share for the quarter. Arecor Therapeutics had a negative net margin of 176.89% and a negative return on equity of 118.67%. Analysts forecast that Arecor Therapeutics plc will post -0.35 earnings per share for the current year.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.